Advances in immuno-based and targeted therapies in extensive-stage small cell lung cancer.

2 The KEYNOTE-604 study demonstrated that in the first-line treatment of patients with ES-SCLC, pembrolizumab plus etoposide and platinum improved progression-free survival (PFS) in patients compared to placebo plus etoposide and platinum, but OS only showed a trend toward benefit and did not reach the threshold of significance (median PFS (mPFS): 4.5 vs 4.3 months, mOS: 10.8 vs 9.7 months). 3 The IMpower133 study first demonstrated that the addition of the anti-PD-L1 monoclonal antibody atezolizumab to carboplatin and etoposide improved PFS and OS in pati

also in 53,322 other papers